Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion

Sobha Sivaprasad,1 Sesan Oyetunde2 1NIHR Biomedical Research Centre, Moorfields Eye Hospital, London, 2Allergan Holdings Ltd., Marlow, UK Purpose: An important factor in the choice of therapy is the impact it has on the patient’s quality of life. This survey aimed to understand treatment...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sivaprasad S, Oyetunde S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	intravitreal injections diabetic macular oedema retinal vein occlusion Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/4e3e16aa2c96463f9ec385ca580bbc88
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4e3e16aa2c96463f9ec385ca580bbc88
record_format	dspace
spelling	oai:doaj.org-article:4e3e16aa2c96463f9ec385ca580bbc882021-12-02T00:17:24ZImpact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion1177-5483https://doaj.org/article/4e3e16aa2c96463f9ec385ca580bbc882016-05-01T00:00:00Zhttps://www.dovepress.com/impact-of-injection-therapy-on-retinal-patients-with-diabetic-macular--peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Sobha Sivaprasad,1 Sesan Oyetunde2 1NIHR Biomedical Research Centre, Moorfields Eye Hospital, London, 2Allergan Holdings Ltd., Marlow, UK Purpose: An important factor in the choice of therapy is the impact it has on the patient’s quality of life. This survey aimed to understand treatment burden, treatment-related anxiety and worry, and practical issues such as appointment attendance and work absence in patients receiving injection therapy for diabetic macular edema (DME) or retinal vein occlusion (RVO).Patients and methods: A European sample of 131 retinal patients completed a detailed questionnaire to elucidate the impact of injection therapy on individuals with DME or RVO.Results: RVO and DME greatly impact a patient’s quality of life. An intensive injection regimen and the requirements for multiple hospital visits place a large practical burden on the patient. Each intravitreal injection appointment (including travel time) was reported to take an average of 4.5 hours, with a total appointment burden over 6 months of 13.5 hours and 20 hours for RVO and DME patients, respectively. This creates a significant burden on patient time and may make appointment attendance difficult. Indeed, 53% of working patients needed to take at least 1 day off work per appointment and 71% of patients required a carer’s assistance at the time of the injection appointment, ~6.3 hours per injection. In addition to practical issues, three-quarters of patients reported experiencing anxiety about their most recent injection treatment, with 54% of patients reporting that they were anxious for at least 2 days prior to the injection. Patients’ most desired improvement to their treatment regimen was to have fewer injections and to require fewer appointments, to achieve the same visual results.Conclusion: Patients’ quality of life is clearly very affected by having to manage an intensive intravitreal injection regimen, with a considerable treatment burden having a large negative effect. Reducing the appointment burden to achieve the same visual outcomes and the provision of additional support for patients to attend appointments would greatly benefit those receiving intravitreal injection therapies for DME and RVO. Keywords: DME, RVO, retina, quality of life, burden, intravitreal, questionnaire Sivaprasad SOyetunde SDove Medical Pressarticleintravitreal injectionsdiabetic macular oedemaretinal vein occlusionOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2016, Iss Issue 1, Pp 939-946 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	intravitreal injections diabetic macular oedema retinal vein occlusion Ophthalmology RE1-994
spellingShingle	intravitreal injections diabetic macular oedema retinal vein occlusion Ophthalmology RE1-994 Sivaprasad S Oyetunde S Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion
description	Sobha Sivaprasad,1 Sesan Oyetunde2 1NIHR Biomedical Research Centre, Moorfields Eye Hospital, London, 2Allergan Holdings Ltd., Marlow, UK Purpose: An important factor in the choice of therapy is the impact it has on the patient’s quality of life. This survey aimed to understand treatment burden, treatment-related anxiety and worry, and practical issues such as appointment attendance and work absence in patients receiving injection therapy for diabetic macular edema (DME) or retinal vein occlusion (RVO).Patients and methods: A European sample of 131 retinal patients completed a detailed questionnaire to elucidate the impact of injection therapy on individuals with DME or RVO.Results: RVO and DME greatly impact a patient’s quality of life. An intensive injection regimen and the requirements for multiple hospital visits place a large practical burden on the patient. Each intravitreal injection appointment (including travel time) was reported to take an average of 4.5 hours, with a total appointment burden over 6 months of 13.5 hours and 20 hours for RVO and DME patients, respectively. This creates a significant burden on patient time and may make appointment attendance difficult. Indeed, 53% of working patients needed to take at least 1 day off work per appointment and 71% of patients required a carer’s assistance at the time of the injection appointment, ~6.3 hours per injection. In addition to practical issues, three-quarters of patients reported experiencing anxiety about their most recent injection treatment, with 54% of patients reporting that they were anxious for at least 2 days prior to the injection. Patients’ most desired improvement to their treatment regimen was to have fewer injections and to require fewer appointments, to achieve the same visual results.Conclusion: Patients’ quality of life is clearly very affected by having to manage an intensive intravitreal injection regimen, with a considerable treatment burden having a large negative effect. Reducing the appointment burden to achieve the same visual outcomes and the provision of additional support for patients to attend appointments would greatly benefit those receiving intravitreal injection therapies for DME and RVO. Keywords: DME, RVO, retina, quality of life, burden, intravitreal, questionnaire
format	article
author	Sivaprasad S Oyetunde S
author_facet	Sivaprasad S Oyetunde S
author_sort	Sivaprasad S
title	Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion
title_short	Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion
title_full	Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion
title_fullStr	Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion
title_full_unstemmed	Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion
title_sort	impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/4e3e16aa2c96463f9ec385ca580bbc88
work_keys_str_mv	AT sivaprasads impactofinjectiontherapyonretinalpatientswithdiabeticmacularedemaorretinalveinocclusion AT oyetundes impactofinjectiontherapyonretinalpatientswithdiabeticmacularedemaorretinalveinocclusion
_version_	1718403798186065920

Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion

Ejemplares similares